坤泰胶囊辅助治疗对绝经后骨质疏松症妇女骨密度、骨代谢和激素水平的影响

目的探讨坤泰胶囊辅助治疗对绝经后骨质疏松症患者骨密度、激素水平和骨代谢的影响。方法 150例绝经后骨质疏松症患者被随机分为治疗组、联合治疗组和对照组,每组50例。治疗组给予雷洛昔芬,联合治疗组给予雷洛昔芬加坤泰胶囊治疗,治疗12个月。检测治疗后两组患者髋部及腰椎的骨密度(bone mineral density,BMD)改变,同时测定血清雌二醇(estradiol,E2)、黄体生成素(luteinizing hormone,LH)、促卵泡剌激素(follicle stimulating hormone,FSH)、骨钙素(OC)和I型胶原交联C-末端肽(CTX-1)的水平,并记录治疗期间出现的药物不良反应。结果对照组的腰椎和髋部BMD在1年后较基线时有不同程度降低,比较差异有统计学意义(P0. 05);治疗1年后,治疗组和联合治疗组髋部及腰椎BMD都有不同程度的升高,且组间比较差异有明显的统计学意义(P0. 05);同时治疗组和联合治疗组血清CTX-1水平均降低,OC水平均升高,两组比较有明显的统计学意义(P0. 05);各组血清FSH和LH水平均降低,E2水平升高,两组比较有明显的统计学意义(P0. 05)。两组患者治疗时均未发现明显药物不良反应。结论坤泰胶囊辅助治疗有助于降低骨转换率,改善性激素水平,改善绝经后女性骨质疏松患者髋部及腰部的骨密度。

Effect of Kuntai capsule adjuvant therapy on bone mineral density, bone metabolism and hormone levels in postmenopausal osteoporosis women

Objective To explore the effects of Kuntai capsule on bone mineral density, hormone levels and bone metabolism in postmenopausal osteoporosis patients. Methods 150 patients with postmenopausal osteoporosis were randomly divided into treatment group, combination treatment group and control group (n=50). The treatment group was given raloxifene and the combination treatment group was treated with raloxifene combined with Kuntai capsule for 12 months. Bone mineral density changes in hip and lumbar spine density were measured after treatment, and serum estradiol (E2), luteinizing hormone (LH), follicle stimulating hormone (FSH), The levels of osteocalcin (OC) and type I collagen cross-linked C-terminal peptide (CTX-1) were tested and adverse drug reactions occurred during treatment were recorded. Results BMD of lumbar vertebrae and hip in the control group decreased to a different extent after 1 year from baseline, and the difference was statistically significant (P<0.05). After 1 year of treatment, the hip and lumbar spine density of the treatment group and the combined treatment group were increased to different degrees, and there was significant statistical significance between the groups (P<0.05). At the same time, the serum CTX-1 level decreased and the OC level increased in the treatment group and the combination treatment group. There was significant statistical significance between the two groups (P<0.05). At the same time, the serum FSH and LH levels in each group decreased, and the E2 level increased. There was significant statistical significance between the two groups (P<0.05). No obvious adverse drug reactions were found in the two groups during treatment. Conclusion Kuntai capsule adjuvant therapy can help reduce bone turnover rate, improve sex hormone levels, and improve bone density in hip and waist in postmenopausal women with osteoporosis.